There’s further drama at troubled Belgian biotech Bone Therapeutics SA, but its CEO told BioWorld that its partner’s decision to return rights to cell therapy platform Allob is a blessing in disguise that could allow it to negotiate a more favorable deal, after a lifeline merger was delayed.